Judit Erchegyi
Tulane University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Judit Erchegyi.
Peptides | 1992
Judit Erchegyi; Abba J. Kastin; James E. Zadina
A novel tetrapeptide, Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1), was purified from extracts of frontal cortex of human brain tissue by several consecutive reversed-phase high performance liquid chromatographic steps followed by a radioimmunoassay originally developed for Tyr-Pro-Leu-Gly-NH2 (Tyr-MIF-1). Sequencing, mass spectrometric analysis, and comparison of its chromatographic behavior with that of the synthetic peptide confirmed the structure. Like Tyr-MIF-1, which was previously isolated from human brain tissue, Tyr-W-MIF-1 can inhibit the binding of 3H-DAMGO (selective for mu opiate receptors) to rat brain and can act as an opiate agonist as well as antagonist. Tyr-W-MIF-1 was a more potent opiate agonist than Tyr-MIF-1, the free acid of Tyr-W-MIF-1, and the structurally related hemoglobin-derived opiate peptide hemorphin-4 (Tyr-Pro-Trp-Thr) in the guinea pig ileum. Each of these peptides acted as opiate antagonists on the ileum from morphine-tolerant guinea pigs; the free acid of Tyr-W-MIF-1 was the most potent antagonist in inhibiting the activity of DAMGO. The results demonstrate the presence in human brain of a new member of the Tyr-MIF-1 family of biologically active peptides.
Brain Research | 1992
Berislav V. Zlokovic; William A. Banks; Hikmat El Kadi; Judit Erchegyi; Jasmina B. Mackic; J. Gordon McComb; Abba J. Kastin
Transport, binding, and metabolism of [phenylalanyl-3,4,5,-3H(N)]arginine vasopressin (AVP) by the blood-brain barrier (BBB) was studied in adult guinea-pigs by means of a novel vascular brain perfusion (VBP)/capillary depletion technique and HPLC. A time-dependent, progressive brain uptake of 3H-radioactivity was measured over the 10 min period of VBP both in brain homogenates and in brain tissue depleted of cerebral microvessels. The unidirectional blood-to-brain transport constant, K(IN), estimated by multiple-time tissue uptake analysis of the homogenate and postcapillary supernatant, indicated that the BBB transfer rate for [3H]AVP (K(IN) = 2.37 +/- 0.25 microliters min-1 per gram brain homogenate) was almost 10 times higher than for simultaneously perfused [14C]sucrose, a cerebrovascular space marker. In contrast to homogenate and postcapillary supernatant, the [3H]radioactivity determined in the vascular pellet after dextran density centrifugation of the brain homogenate was very low and only somewhat higher than for [14C]sucrose. HPLC analysis of the perfused brain tissue revealed time-dependent degradation of the blood-borne neuropeptide. The percentage of intact [3H]AVP as determined in the postcapillary supernatant progressively declined during brain perfusion, from 49% at 1 min to 11.9% at 10 min. The major detectable labeled metabolite was [3H]phenylalanine, the labeled amino acid residue of [3H]AVP. The aminopeptidase inhibitor bestatin (0.5 mM), perfused simultaneously with [3H]AVP by the VBP technique, did not alter tissue uptake of [3H]AVP, indicating that there was no significant hydrolysis of peptide by the luminal BBB surface.(ABSTRACT TRUNCATED AT 250 WORDS)
Neuropeptides | 1993
Laszlo Hackler; Abba J. Kastin; Judit Erchegyi; James E. Zadina
Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) was recently isolated from human brain cortex. We have now isolated it from bovine hypothalami by solid phase extraction and several consecutive rpHPLC steps monitored by an RIA originally developed for the endogenous brain peptide Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2). Determination of the sequence of the purified material and comparison of its chromatographic behavior with synthetic Tyr-W-MIF-1 confirmed the structure. The synthetic peptide and the isolated material showed almost identical binding to mu opiate receptors.
Biochemical and Biophysical Research Communications | 1981
Judit Erchegyi; D.H. Coy; Mary V. Nekola; Esther J. Coy; A. V. Schally; Imre Mezo; Istvan Teplan
Abstract A series of LH-RH antagonist analogs has been developed in which inhibitory activities have been increased to a potentially clinically useful level. The new peptides, which are typified by [N-acetyl-D-p-Cl-Phe 1,2 , D-Trp 3 , D-Phe 6 ,D-Ala 10 ]-LH-RH and [N-acetyl-D-Trp 1,3 ,D-p-Cl-Phe 2 ,D-Phe 6 , D-Ala 10 ]-LH-RH, most importantly contain new modification to positions 1, 2 and 10, and induce full blockade of ovulation at single doses as low as 10 μg per rat (50 μg/kg). Various ring substituents on D-Trp or D-Phe in position 1 or other D-amino acid replacements in position 10 did not significantly improve anti-ovulatory activity. Incorporation of N-Me-Leu in position 7 was slightly detrimental to activity.
Biochemical Pharmacology | 1994
Abba J. Kastin; Kathy Hahn; Judit Erchegyi; James E. Zadina; Laszlo Hackler; Muriel S. Palmgren; William A. Banks
The metabolism of the endogenous brain peptides Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2) and MIF-1 (Pro-Leu-Gly-NH2) was determined by HPLC after incubation of the tritiated peptides in human and rat plasma. Degradation of Tyr-MIF-1 was rapid in the plasma from both species, in contrast to the slightly delayed degradation of MIF-1 in rat plasma and the extremely prolonged persistence of MIF-1 in human plasma. In rat plasma, more than half of the intact Tyr-MIF-1 and MIF-1 was degraded within 5 min, in contrast to the 5 days required for 50% degradation of MIF-1 in human plasma at 37 degrees. To slow the rapid rate of metabolism, studies were then performed at 0 degree. Incubation of Tyr-MIF-1 in human plasma at 0 degree for 2 hr resulted in HPLC identification of more Tyr-Pro than Tyr at all times. At 0 degree in rat plasma, however, more Tyr than Tyr-Pro was formed after the first 5 min of incubation of the Tyr-MIF-1 that was labeled on the Tyr. This raised the possibility that the tetrapeptide Tyr-MIF-1 might be serving as a precursor of the tripeptide MIF-1. Incubation of Tyr-MIF-1 tritiated at the Pro under the same conditions with and without Tyr-MIF-1 tritiated at the Tyr showed that Tyr-Pro, not MIF-1, was the predominant degradation product of Tyr-MIF-1. In addition to the metabolism of Tyr-MIF-1 being slower at lower temperatures, it was also slowed by some enzyme inhibitors. After 10 min of incubation at 37 degrees, EDTA appeared to be more effective than bestatin, p-chloromercuribenzoic acid (PCMB), pepstatin, or aprotinin, but after 30 min, bestatin was more effective. Intravenous injection of the tritiated peptides into rats showed short half-time disappearances; again, MIF-1 persisted in blood longer than Tyr-MIF-1. Thus, the results show the rapid metabolism of Tyr-MIF-1 in human and rat plasma, the slightly slower metabolism of MIF-1 in rat plasma, the predominant formation of Tyr-Pro rather than MIF-1 from Tyr-MIF-1, and the markedly delayed metabolism of MIF-1 in human plasma.
Archive | 1999
György Kéri; Laszlo Orfi; Ferenc Hollósy; Tibor Vántus; Judit Erchegyi; Miklós Idei; Aniko Horvath; Istvan Teplan; Aviv Gazit; István Peták; Zsolt Szegedi; Béla Szende
G. KÉRI, L. ÔRFI1, F. HOLLÓSY, T. VÁNTUS, J. ÉRCHEGYI, M. IDEI, A. HORVÁTH, I. TEPLÁN, A. GAZIT3, I. PETÁK2, Z. SZEGEDI2 and B. SZENDE2 Peptide Biochem Res Unit., Dept of Medical Chemistry, 1Institute of Pharmaceutical Chemistry, and 2 1st Institute of Pathology Semmelweis University of Medicine, Budapest, P.O.Box 260, Hungary-1444, 3 Dept. of Biol. Chemistry, The Hebrew University of Jerusalem, Israel-91904
Endocrinology | 1982
David H. Coy; Aniko Horvath; Mary V. Nekola; Esther J. Coy; Judit Erchegyi; Andrew V. Schally
International Journal of Peptide and Protein Research | 2009
Judit Erchegyi; Abba J. Kastin; James E. Zadina; Xiu‐Di Qiu
Archive | 1983
F. Antoni; Judit Erchegyi; Aniko Horvath; Gyorgi Keri; Imre Mezo; Karoly Nikolics; Janos Seprodi; Andras Szell; Balazs Szoke; Istvan Teplan
Archive | 2001
Gyorgy Keri; János Szolcsányi; Erika Pintér; Zsuzsanna Helyes; Judit Erchegyi; Aniko Horvath; Judith Horváth; Istvan Teplan; Laszlo Orfi